Current Report Filing (8-k)
April 06 2023 - 4:25PM
Edgar (US Regulatory)
false000150549700015054972023-04-062023-04-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 6, 2023
BioRestorative Therapies, Inc.
(Exact name of registrant as specified in its charter)
Nevada
|
|
001-37603
|
|
30-1341024
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
40 Marcus Drive
Melville, New York
|
|
11747
|
(Address of principal executive offices)
|
|
(Zip code)
|
Registrant's telephone number, including area code (631) 760-8100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
BRTX
|
NASDAQ Capital Market
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
of 1934 (§240.12b-2 of this chapter):
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
This Current Report on Form 8-K is being filed solely to file the consents of Friedman LLP, formerly the independent
registered public accounting firm of BioRestorative Therapies, Inc. (the “Company”), and Marcum LLP, currently the independent registered accounting firm of the Company, each dated April 6, 2023, to the incorporation by reference of their reports
dated March 30, 2022 and March 24, 2023, respectively, relating to the consolidated financial statements of the Company and Subsidiary included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) filed
with the Securities and Exchange Commission on March 27, 2023, into the Company’s Registration Statement on Form S-3 (No. 333-258611). The consents filed as Exhibit 23.1 and Exhibit 23.2 to this Current Report are in addition to, and do not change,
the previously filed consents of Friedman LLP and Marcum LLP filed as Exhibit 23.1 and Exhibit 23.2, respectively, to the Form 10-K.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
|
|
Description
|
23.1
|
|
Independent Registered Public Accounting Firm’s Consent
|
23.2
|
|
Independent Registered Public Accounting Firm’s Consent
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
BIORESTORATIVE THERAPIES, INC.
|
|
|
|
|
|
Dated: April 6, 2023
|
By:
|
/s/ Lance Alstodt
|
|
|
|
Lance Alstodt
|
|
|
|
President and CEO
|
|
|
|
|
|
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jul 2023 to Jul 2024